Effective expression and purification of recombinant onconase, an antitumor protein

E Notomista1, V Cafaro, R Fusiello

  • 1Dipartimentó di Chimica Organica e Biologica, Università di Napoli Federico II, Via Mezzocannone 16, 80134, Naples, Italy.

FEBS Letters
|December 22, 1999
PubMed

Insights

Researchers successfully produced recombinant onconase, an antitumor enzyme, in bacteria. This engineered onconase exhibits identical biological and catalytic properties to the natural enzyme, supporting its therapeutic potential.

Area of Science:

  • Biochemistry
  • Molecular Biology
  • Oncology

Background:

  • The RNase A superfamily contains enzymes with antitumor properties.
  • Onconase, the smallest RNase A member, shows selective cytotoxicity against tumor cells and is in clinical trials.

Purpose of the Study:

  • To express and purify recombinant onconase in Escherichia coli.
  • To confirm the biological and catalytic identity of the recombinant protein compared to the natural enzyme.

Main Methods:

  • Expression of recombinant onconase in E. coli inclusion bodies.
  • Protein processing and purification techniques.
  • Assessment of biological and catalytic activity.

Main Results:

  • High yields of correctly processed recombinant onconase were obtained.
  • The recombinant onconase demonstrated identical biological and catalytic properties to the natural enzyme.

Conclusions:

  • Recombinant onconase can be efficiently produced with preserved functionality.
  • This production method supports further development and clinical application of onconase as an antitumor agent.